Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Checkmate Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11018
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) that converts immunologically cold tumors to immunologically hot tumors. It also evaluates CMP-001-001, an open label study of intratumoral administration of CMP-001 in combination with pembrolizumab in patients with advanced cutaneous melanoma. Checkmate Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Checkmate Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Partnerships 13
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Licensing Agreements 16
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc – Key Competitors 17
Checkmate Pharmaceuticals Inc – Key Employees 18
Checkmate Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
Apr 24, 2018: Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer 20
Apr 17, 2018: Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc, Key Competitors 17
Checkmate Pharmaceuticals Inc, Key Employees 18

List of Figures
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kyochon F&B Co., Ltd.
    Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pernod Ricard SA:戦略・SWOT・企業財務分析
    Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report Summary Pernod Ricard SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Coloplast AS (COLO B):医療機器:M&Aディール及び事業提携情報
    Summary Coloplast A/S (Coloplast) is a medical device company that offers products and services for ostomy care, urology care, continence care, and skin and wound care. Its major products include ostomy bags; urisheaths; urine bags; catheters; anal irrigation systems; vaginal sling products; advance …
  • Knopp Biosciences LLC-製薬・医療分野:企業M&A・提携分析
    Summary Knopp Biosciences LLC (Knopp Biosciences) is a drug discovery and development company that develops and markets medicines for the treatment of neurological disorders. The company's lead product candidate, dexpramipexole, is an orally bioavailable small molecule which is used for the treatmen …
  • Nuvaira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Nuvaira Inc (Nuvaira), formerly Holaira Inc is an independent medical device company that strives to develop minimally invasive products for the treatment of obstructive lung diseases. It provides Lung Denervation System, a catheter-based system intended for asthma and chronic obstructive pu …
  • BerGenBio ASA (BGBIO)-製薬・医療分野:企業M&A・提携分析
    Summary BerGenBio ASA (BerGenBio) is a developer of drugs for aggressive and drug resistant cancers. The company develops epithelial-mesenchymal transition inhibitors for acquired cancer drug-resistance and metastasis. Its BGB324 finds application in the treatment of drug resistant chronic myeloid l …
  • Nuri Telecom Co., Ltd. (040160):企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Walgreens Boots Alliance, Inc.:企業の戦略・SWOT・財務情報
    Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Applied Genetic Technologies Corp (AGTC):企業の財務・戦略的SWOT分析
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. AGTC offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis …
  • MedImmune LLC:企業のM&A・事業提携・投資動向
    MedImmune LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MedImmune LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Antero Resources Corp (AR):企業の財務・戦略的SWOT分析
    Antero Resources Corp (AR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Pricer AB (PRIC B):企業の財務・戦略的SWOT分析
    Pricer AB (PRIC B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • American Axle & Manufacturing Holdings, Inc.
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Partners HealthCare System Inc:企業の戦略的SWOT分析
    Partners HealthCare System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Holland Colours NV (HOLCO):企業の財務・戦略的SWOT分析
    Holland Colours NV (HOLCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Samsung Heavy Industries Co., Ltd.
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Duke Energy Corp:企業の発電所・SWOT分析2018
    Duke Energy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Targovax ASA (TRVX):企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipelin …
  • Evofem Inc-医療機器分野:企業M&A・提携分析
    Summary Evofem Inc (Evofem) is a healthcare solution provider that discovers, develops and commercializes prescription and consumer products. The company’s product pipeline includes amphora and nestorone. Evofem improves reproductive health and wellness options for women. It develops products for co …
  • Groupe Guillin SA:企業の戦略・SWOT・財務情報
    Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report Summary Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆